financetom
Business
financetom
/
Business
/
What's Going On With Intel Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Intel Stock?
Jul 26, 2024 9:49 AM

Intel Corp ( INTC ) shares are trading flat Friday and lower by some 6.6% to $31.10 for the week. This decline comes amid sector-wide pressure from recent earnings reports and looming concerns over potential new restrictions on China.

What’s Happening?

The semiconductor sector has experienced heightened volatility recently. President Biden is contemplating additional measures against China, which is causing uncertainty in the market. Furthermore, former President Donald Trump’s remarks during a recent Bloomberg interview regarding the China-Taiwan conflict have stoked fears of political and economic instability. Trump’s suggestion of a possible shift in U.S. policy toward Taiwan could threaten Intel’s supply chain.

Geopolitical tensions are exacerbating investor concerns about supply chain disruptions, potential tariffs and sanctions. As a leading company in the semiconductor industry, Intel ( INTC ) is particularly vulnerable to these risks.

Read Also: Why Taiwan Semiconductor Manufacturing Company Shares Are Volatile This Week

What Else?

As the U.S. government considers additional restrictions on China, there may be increased investment in domestic semiconductor manufacturing. Intel ( INTC ), being a leading U.S.-based semiconductor company, could benefit from government incentives and subsidies aimed at boosting domestic production.

Additionally, geopolitical tensions might accelerate technological innovation within the U.S. semiconductor industry. Intel ( INTC ), with its strong research and development capabilities, could lead in developing new technologies, giving it a competitive edge.

Read Also: Fed’s Favorite Inflation Gauge Falls To 2.5%, Lowest Since February 2021

Is INTC A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Intel ( INTC )‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Intel ( INTC ) does pay a dividend, which yields 1.36% per year as of the closing price on Jul. 26, 2024. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 19.89%, you'll need to buy a share of Oxford Lane Capital by the Dec. 17, 2024. Once done, you can expect to receive a nominal payout of $0.09 on Dec. 31, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Intel ( INTC ) will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, INTC has a 52-week high of $51.28 and a 52-week low of $29.73.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enliven Therapeutics Insider Sold Shares Worth $279,155, According to a Recent SEC Filing
Enliven Therapeutics Insider Sold Shares Worth $279,155, According to a Recent SEC Filing
Nov 21, 2025
05:33 PM EST, 11/21/2025 (MT Newswires) -- Joseph P Lyssikatos, Chief Scientific Officer, on November 19, 2025, sold 12,500 shares in Enliven Therapeutics ( ELVN ) for $279,155. Following the Form 4 filing with the SEC, Lyssikatos has control over a total of 902,688 common shares of the company, with 902,688 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1672619/000196715025000007/xslF345X05/form4-11212025_101158.xml ...
US CFPB settles with MoneyLion as enforcement activity winds down
US CFPB settles with MoneyLion as enforcement activity winds down
Nov 21, 2025
NEW YORK (Reuters) -The U.S. Consumer Financial Protection Bureau reached a $1.75 million settlement with MoneyLion to settle charges that the online lender overcharged military personnel on loans, in possibly one of the agency's final actions as it winds down enforcement activity. MoneyLion, a unit of Gen Digital ( GEN ), had been accused in a September 2022 lawsuit filed...
United Therapeutics Insider Sold Shares Worth $3,812,082, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $3,812,082, According to a Recent SEC Filing
Nov 21, 2025
05:34 PM EST, 11/21/2025 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & CEO, on November 20, 2025, sold 8,000 shares in United Therapeutics ( UTHR ) for $3,812,082. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 644,489 common shares of the company, with 130 shares held directly and 644,359 controlled indirectly. SEC...
Bill Ackman eyes IPO of hedge fund Pershing in early 2026, FT reports
Bill Ackman eyes IPO of hedge fund Pershing in early 2026, FT reports
Nov 21, 2025
Nov 21 (Reuters) - Billionaire investor Bill Ackman is aiming to publicly list hedge fund company, Pershing Square Capital Management, early next year, the Financial Times reported on Friday, citing two people briefed on the matter. (Reporting by Ateev Bhandari in Bengaluru; Editing by Arun Koyyur) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved